Cytokeratin-derived markersof lung cancer

Expert Review of Molecular Diagnostics

Volumn 1, Issue 3, 2001, Pages 315-322

  Buccheri, Gianfranco ^a   Ferrigno, Domenico ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

cytokeratin 19 fragments; diagnosis; lung cancer; non small cell lung cancer; prognosis; staging; tissue polypeptide antigen; tissue polypeptide specific antigen; treatment response evaluation; tumor markers

Indexed keywords

CYTOKERATIN; CYTOKERATIN 19 FRAGMENT; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

CANCER INVASION; CANCER SCREENING; CYTOSKELETON; DIAGNOSTIC ACCURACY; LUNG CANCER; MEDIASTINOSCOPY; NON INVASIVE MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; REVIEW; THORAX RADIOGRAPHY;

ANTIGENS, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KERATINS; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0035559537     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.1.3.315     Document Type: Review

References (79)

1. Minna JD, Higgins GA, Glatstein EJ.Cancer of the lung. In: Cancer Principles and Practice of Oncology (2nd Edition). De Vita VT, Jr., Hellman S, Rosemberg SA (Eds.), JB Lippincott, Philadelphia, USA, 507 – 597 (1985).
2. Luna EJ, Hitt AL. Cytoskeleton-plasma membrane interactions. Science 258, 955 – 963 (1992).
3. Lazarides E. Intermediate filaments as mechanical integrators of cellular space. Nature 283, 249 – 256 (1980).
4. Debus E, Moll R, Franke WW, Weber K, Osborn M. Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. Am. Pathol 114, 121 – 130 (1984).
5. Sundstrom BE, Stigbrand TI. Cytokeratins and tissue polypeptide antigen. int. J. Biol. Markers 9 (2), 102 – 108 (1994).
6. Broers JL, Ramaekers PC, Rot MK et al. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res. 48, 3221 – 3229 (1988).
7. Stieber P, Dienemann H, Hasholzner U et al Comparison of CYFRA 21 – 1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int. j Biol. Markers 9, 82 – 88 (1994).
8. Ferrigno D, Buccheri G, Biggi A. Serum tumour markers in lung cancer: history, biology and clinical applications. Eric Respir. 7 (1), 186 – 197 (1994).
9. Nildinski J, Furman M. Clinical tumour markers in lung cancer. Eur. j Cancer Prey. 4 (2), 129 – 138 (1995).
10. Ferrigno D, Buccheri G. Clinical applications of serum markers for lung cancer. Respir. Med. 89, 587 – 597 (1995).
11. Buccheri G. Tumor markers: clinical meaning and use. In: Lung Tumors (1st Edition). Brambilla C, Brambilla E (Eds.), Marcel Dekker, New York, USA, 435 – 452 (1999).
12. Bjorldund B. Serological analysis of human cancer antigen. Proc. VI Int.CongressNlicrobiol Rome, Italy, 344 (1953).
13. Bjorldund B, Bjorldund V. Antigenicity of pooled human malignant and normal tissues by cytoimmunological technique: presence of an insoluble, heat-labile tumor antigen. Int. Arch. Allergy 10, 153 – 184 (1957).
14. B., Bjorldund, G., Lundblad, V., Bjorldund, Antigenicity of pooled human malignant and normal tissues by cytoimmunological technique: II. Nature of tumor antigen, Int. Airh. Allergy, (1958), 12, 241-261
15. Bjorklund B, Bjorklund V, Wiklund B et al. A human tissue polypeptide related to cancer and placenta: I. preparation and properties, II. Assay technique, III. Clinical studies of 1483 individuals with cancer and other conditions. In: Immunological Techniques for Detection of Cancer. Bjorklund B (Ed.), Bonniers, Stockholm, Sweden, 133 – 187 (1973).
16. Luning B, Nilsson U. Sequence homology between tissue polypeptide antigen (TPA) and intermediate filament (IF) proteins. Acta Chem. Scand B 37, 731 – 733 (1983).
17. Weber K, Osborn M, Moll R, Wiklund B, Luning B. Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8,18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker. EMI30 J. 3 (11), 2707 – 2714 (1984).
18. Pujol JL, Grenier J, Parrat E et al. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21 – 1 and TPS. Am. Respir. Grit Care Med 154 (3 Pt 1), 725 – 733 (1996).
19. Pujol JL, Cooper EH, Grenier J et al. Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancer. Eur. j Cancer 30A(12), 1768 – 1774 (1994).
20. H., Bodenmuller, D., Banauch, B., Ofenloch, D., Jaworek, A., Dessauer, Technical evaluation of a new automated tumor marker assay: the Enzymun-Test CYFRA 211. In: Tumor-Associatecl Antigens, Oncogens, Receptors, Cytochines in Tumor Diagnosis and Therapy at the Beginning of the 90th., KLapdor R (Ed.), Springer Verlag, Berlin, Germany, (1992), 137-138
21. Buccheri G. Circulating biomarkers for lung cancer. Ann. Ital. Chir. 70 (6), 831 – 838 (1999).
22. Buccheri G, Ferrigno D. The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer: diagnostic yield and comparison with conventional staging methods. Chest 107, 471 – 476 (1995).
23. Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur. Respir. 7 (7), 1350 – 1364 (1994).
24. Gold P, Freedman SO. Demonstration of tumor-specific antigenin in human colonic carcinomata by immunological tolerance and absorption techniques. I Exp. Med. 121, 439 – 462 (1965).
25. Coombes RC, Powels TJ. Tumour markers in the management of human cancer. In: Topical Reviews in Radiotherapy and Oncology Deeley TJ (Ed.), Wright PGS, Bristol, USA, 39 (1982).
26. Buccheri G, Violante B, Sartoris AM, Ferrigno D, Curcio A, Vola E Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer 57, 2389 – 2396 (1986).
27. Buccheri G, Ferrigno D, Sartoris AM, Violante B, Vola F, Curcio A. Tumor markers in bronchogenic carcinoma: superiority of tissue polyptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer 60, 42 – 50 (1987).
28. Buccheri G, Ferrigno D. Usefulness of tissue polypeptide antigen in staging, monitoring and prognosis of lung cancer. Chest 93, 565 – 569 (1988).
29. Buccheri G, Ferrigno D. Prognostic value of the tissue polyptide antigen in lung cancer. Chest 101, 1287 – 1292 (1992).
30. Buccheri G, Ferrigno D, Vola Carcinoembryonic antigen (CEA), tissue polyptide antigen (TPA) and other prognostic indicators in the squamous cell carcinoma of the lung. Lung- Cancer 10, 21 – 33 (1993).
31. Buccheri G, Ferrigno D. Monitoring lung cancer with tissue polyptide antigen: an ancillary, profitable serum test to evaluate treatment response and post-treatment disease status. Lung- Cancer 13, 155 – 168 (1995).
32. G., Buccheri, D., Ferrigno, Serum biomarkers of non-neuron-endocrine origin in small-cell lung cancer: a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase, Lung- Cancer, (2000), 30, 1, 37-49
33. Mizushima Y, Hirata H, Izumi S, et al Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cancer with multiple tumor marker assay. Oncology 47, 43 – 48 (1990).
34. Gronowitz JS, Bergstrom R, Nou E et al. Clinical and serologic markers of stage and prognosis in small cell lung cancer. Cancer 66, 722 – 732 (1990).
35. Van der Gaast A, Van Putten WL, Oosterom R, Cozijnsen M, Hoekstra R, Splinter TA. Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neurone specific enolase in patients with small cell lung cancer. BE Cancer 64, 369 – 372 (1991).
36. Van der Gaast A, Kok TC, Kho GS, Blijenberg BG, Splinter TAW Disease monitoring by the tumour markers Cyfra 21.1 and TPA in patients with non-small cell lung cancer. Eur j Cancer31A, 1790 – 1793 (1995).
37. D., Rastel, A., Ramaioli, F., Cornillie, B., Thirion, CYFRA 211, a sensitive and specific new tumour marker for squamous cell lung cancer., Report of the first European multicentre evaluation. Eur. j Cancer 30A, (1994), 601-606
38. Correale M, Arnberg H, Blockx P et al Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. Int. j Biol. Markets 9, 231 – 238 (1994).
39. Plebani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results. Brj Cancer 72, 170 – 173 (1995).
40. Trevisani L, Putinati S, Sartori S, Abbasciano V, Bagni B. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer. Chest 109, 104 – 108 (1996).
41. Kashiwabara K, Nakamura H, Kiguchi T et al Correlation between serum cytokeratin 19 fragments and tissue polypeptide antigen levels in patients with non-small cell lung cancer. Clin. Chim. Acta 266 (2), 149 – 155 (1997).
42. W., Ebert, M., Hoppe, T., Muley, Drings Monitoring of therapy in inoperable lung cancer patients by measurement ofCYFRA 21 – 1, TPA- TP CEA and NSE, Anticancer Res., (1997), 17, 4B, 2875-2878
43. Bates J, Rutherford R, Divilly M, et al Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. Eur Respir. 10 (11), 2535 – 2538 (1997).
44. Foa P, Fornier M, Miceli R, et al Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non- small cell lung cancer. Anticancer Res. 19(4C), 3613 – 3618 (1999).
45. Watine J, Charet JC. [Primary small-cell bronchial cancer: value of serum tumor markers in the prognostic evaluation]. Pmsse Med. 28 (28), 1541 – 1546 (1999).
46. Prados C, Alvarez-Sala R, Gomez dT et al. An evaluation of tissue polypeptide antigen (TPA) in the two bronchoalveolar lavage fractions of lung cancer patients. Jpn. Clin. Oncol 30 (5), 215 – 220 (2000).
47. Rapellino M, Pecchio F, Baldi S, Scappaticci E, Cavallo A. Clinical utility of tissue polypeptide antigen determination in lung cancer management. Anticancer Res. 15, 1065 – 1070 (1995).
48. Ferrigno D, Buccheri G, Rendine S. The prognostic value of CEA and TPA in the initial evaluation of lung cancer: results of a multivariate analysis of 312 patients. In: Lung Cancer: Advanced Concepts and Present Status. Motta G (Ed.), IASLG, Genova, Italy, 179 – 188 (1989).
49. Marino P, Buccheri G, Preatoni A, Ferrigno D, Luporini AC, Pravettoni G. Tissue polypeptide specific antigen (TPS) and objective response to treatment in solid tumors. Int. Biol. Markers 7, 65 – 67 (1992).
50. Giovanella L, Ceriani L, Bandera M, Rimoldi R, Beghe B, Roncari G. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non-small cell lung cancer evaluation. Q. J. Nucl. Med. 39 (4), 285 – 289 (1995).
51. L., Giovanella, L., Ceriani, M., Bandera, B., Beghe, G., Roncari, Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer, Int. J. Biol. Markeis, (1995), 10, 3, 156-160
52. A., Van der Gaast, C.H., Schoenmakers, T.C., Kok, B.G., Blijenberg, W.C., Hop, T.A., Splinter, Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer, Eur I Cancer, (1994), 30, 12, 1783-1786
53. Ray P, Quantin X, Grenier J, Pujol JL. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect. Prey. 22 (4), 293 – 304 (1998).
54. Nisman B, Lafair J, Heching N, et al Evaluation of tissue polypeptide specific antigen, CYFRA 21-1 and carcinoembryonic antigen in nonsmall cell lung carcinoma — does the combined use of cytokeratin markers give any additional information. Cancer 82, 1850 – 1859 (1998).
55. Boher JM, Pujol JL, Grenier J, Daures JP. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21 – 1 and TPS levels on prognosis. Br. J. Cancer 79(9 – 10), 1419–1427 (1999).
56. Nisman B, Amir G, Lafair J et al. Prognostic value of CYFRA 21 – 1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res. 19(4C), 3549–3552 (1999).
57. Ebert W, Leichtweis B, Schapohler B, Muley TH. The new tumor marker CYFRA 21 – 1 is superior to SCC antigen and CEA in the primary diagnosis of lung cancer. Tumor Diagn. Thec 3, 91 – 99 (1993).
58. Ebert W, Muley T CYFRA 21 – 1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. Anticancer Res. 19 (4A), 2669–2672 (1999).
59. Stieber P, Hasholzner U, Bodenmüller H et al CYFRA 21-1: A new marker in lung cancer. Cancer 72, 707 – 713 (1993).
60. Stieber P, Zimmermann A, Reinmiedl J, Muller C, Hoffmann H, Dienemann H. CYFRA 21 – 1 in the early diagnosis of recurrent disease in non-small cell lung carcinomas (NSCLC). Anticancer Res. 19(4A), 2665–2668 (1999).
61. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 53, 61 – 66 (1993).
62. J., Pujol, J., Boher, J., Grenier, X., Quantin, Cyfra 211, neurone specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients, Lung-Cancer, (2001), 31, 2, 3, 221-231
63. Sugama Y, Kitamura S, Kawai T et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: Measurement of serum cytokeratin fragment. Jpn. 1 Cancer Res. 85,1178-1184 (1994).
64. Van der Gaast A, Schoenmakers C III I, Kok TC, Blijenberg BG, Cornillie F, Splinter TAW Evaluation of a new tumour marker in patients with non-small cell lung cancer: CIFRA 21 – 1. Br. Cancer 69, 525 – 528 (1994).
65. Nildinski J, Furman M, Chyczewska E, Chyczewski L, Rogowski F, Laudanski J. Diagnostic and prognostic value of the new tumour marker CIFRA 21 – 1 in patients with squamous cell lung cancer. Eur. Resp. J. 8,291-294 (1995).
66. Nildinski J, Furman M, Burzykowski T et al Preoperative CYFRA 21 – 1 level as a prognostic indicator in resected primary squamous cell lung cancer. Br. J. Cancer 74, 956 – 960 (1996).
67. Nildinski J, Burzykowski T, Niklinska W et al Preoperative CYFRA 21 – 1 level as a prognostic indicator in resected non-small cell lung cancer. Eur. Rasp. 12,1424-1428 (1998).
68. Takada M, Masuda N, Matsuura E et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21 – 1 enzyme immunoassay. Br. J. Cancer 71, 160 – 165 (1995).
69. Muraki M, Tohda Y, Iwanaga T, Uejima H, Nagasaka Y, Nakajima S. Assessment of serum CYFRA 21-1 in lung cancer. Cancer 77, 1274 – 1277 (1996).
70. Lai RS, Hsu HK, Lu JY, Ger LP, Lai NS. CYFRA 21 – 1 enzyme-linked immunosorbent assay — evaluation as a tumor marker in non-small cell lung cancer. Chest 109, 995 – 1000 (1996).
71. Maeda Y, Segawa Y, Takigawa N, Takata I, Fujimoto N. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer. InternMed 35, 764 – 771 (1996).
72. Huang MS, Jong SB, Tsai MS et al. Comparison of cytokeratin fragment 19 (CYFRA 21 – 1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Respir. Med. 91 (3), 135 – 142 (1997).
73. Kashiwabara K, Nakamura H, Esaki T Serum cytokeratin 19 fragment levels in non-small cell lung cancer patients according to T factor in the TNM classification. Clip. Chim. Acta 288(1 – 2), 153 – 159 (1999).
74. Bréchot JM, Chevret S, Nataf J et al Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur Cancer 33, 385 – 391 (1997).
75. Hirashima T, Takada M, Komiya T et al. Prognostic significance of CYFRA 21 – 1 in non-small cell lung cancer. Anticancer Res. 18(6B), 4713–4716 (1998).
76. Seemann MD, Beinert T, Furst H, Fink U. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21 – 1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. Lung- Cancer 26 (3), 149 – 155 (1999).
77. Huang MS, Jong SB, Lin MS et al. Cytokeratin fragment 19 (CYFRA 21 – 1) as a tumor marker in non-small cell lung cancer. Kao. Iliung. I Hsueh. Ko. Hsueh. Tsa. Chili. 12,62-68 (1996).
78. Dienemann H, Stieber P, Zimmermann A, Hoffmann H, Muller C, Banauch D. Tumor-marker CYFRA 21 – 1 in non-small cell lung cancer (NSCLC): role for detection of recurrence. Lung Cancer 11 (supp1.1), 46 (1994).
79. American Thoracic Society, European Respiratory Society. Pretreatment evaluation of non-small cell lung cancer. Am.1. Respir. Grit. Cam Med. 156,320-332 (1998).